-
Oct 9, 2024 | 
nature.com | Ferdinandos Skoulidis |Ana Cobo |Meagan Montesion |Yi Yu |Natalie I. Vokes |Joseph Murray | +44 more
AbstractFor patients with advanced non-small-cell lung cancer (NSCLC), dual immune checkpoint blockade (ICB) with CTLA4 inhibitors and PD-1 or PD-L1 inhibitors (hereafter, PD-(L)1 inhibitors) is associated with higher rates of anti-tumour activity and immune-related toxicities, when compared with treatment with PD-(L)1 inhibitors alone. However, there are currently no validated biomarkers to identify which patients will benefit from dual ICB1,2.
-
Feb 13, 2024 | 
nature.com | Benjamin Besse |Sylvia Hartl |Patrick M. Forde |Melissa Johnson |Dong-Wan Kim |Boaz E. Aronson | +7 more
AbstractFor patients with non-small-cell lung cancer (NSCLC) tumors without currently targetable molecular alterations, standard-of-care treatment is immunotherapy with anti-PD-(L)1 checkpoint inhibitors, alone or with platinum-doublet therapy. However, not all patients derive durable benefit and resistance to immune checkpoint blockade is common.
-
Feb 11, 2024 | 
dx.doi.org | Cameron Milne |Rijian Song |Melissa Johnson |Chunyu Zhao
Following traumatic lacerations and surgical incisions, staples and sutures are the primary means for stopping bleeding, fluid egress, and achieving wound closure. (1−3) Although these materials are endowed with high tensile strength, they are precluded by being time-consuming to administer, causing additional damage to the wound and increasing the risk of bacterial infiltration and subsequent infection.
-
Nov 28, 2023 | 
onclive.com | Melissa Johnson
November 28, 2023Melissa L. Johnson, MD, discusses the preliminary efficacy findings from the phase 1 RMC-6236-001 trial in patients with non–small cell lung cancer harboring KRAS mutations and details the significance of these findings for patients within the KRAS G12X-mutant NSCLC population. Melissa L.
-
Sep 18, 2023 | 
onclive.com | Melissa Johnson
Melissa L. Johnson, MD, director, Lung Cancer Research, Sarah Cannon Research Institute; chair, Oncology Department, member, Medical Executive Committee, TriStar Centennial Medical Center, discusses findings from a subgroup analysis of outcomes with ifinatamab deruxtecan (I-DXd; DS-7300) in patients with refractory small cell lung cancer (SCLC), which she presented at the 2023 IASLC World Conference on Lung Cancer.
-
Sep 18, 2023 | 
onclive.com | Melissa Johnson
Melissa L. Johnson, MD, director, Lung Cancer Research, Sarah Cannon Research Institute; chair, Oncology Department, member, Medical Executive Committee, TriStar Centennial Medical Center, discusses findings from a subgroup analysis of outcomes with infinatamab deruxtecan (I-DXd; DS-7300) in patients with refractory small cell lung cancer (SCLC), which she presented at the 2023 IASLC World Conference on Lung Cancer.
-
Jul 27, 2023 | 
nature.com | Raffit Hassan |Marcus Butler |Roisin E. O’Cearbhaill |Melissa Johnson |Nirali Shah |Babak Saboury | +2 more
AbstractThe T cell receptor fusion construct (TRuC) gavocabtagene autoleucel (gavo-cel) consists of single-domain anti-mesothelin antibody that integrates into the endogenous T cell receptor (TCR) and engages the signaling capacity of the entire TCR upon mesothelin binding. Here we describe phase 1 results from an ongoing phase1/2 trial of gavo-cel in patients with treatment-refractory mesothelin-expressing solid tumors.
-
Jul 20, 2023 | 
onclive.com | Melissa Johnson
Melissa L. Johnson, MD, director, Lung Cancer Research, Sarah Cannon Research Institute; chair, Oncology Department, member, Medical Executive Committee, TriStar Centennial Medical Center, discusses the development of the seizure-related homolog protein 6 (SEZ6)–targeting antibody-drug conjugate (ADC) ABBV-011 and outcomes with this agent in patients with small cell lung cancer (SCLC).
-
Jun 8, 2023 | 
onclive.com | Melissa Johnson
Melissa L. Johnson, MD, director, Lung Cancer Research, Sarah Cannon Research Institute; chair, Oncology Department, member, Medical Executive Committee, TriStar Centennial Medical Center, discusses findings from the phase 2 ARC-7 trial (NCT04262856) in patients with previously untreated metastatic, PD-L1–high non–small cell lung cancer (NSCLC).
-
Jun 8, 2023 | 
onclive.com | Melissa Johnson
Melissa L. Johnson, MD, director, Lung Cancer Research, Sarah Cannon Research Institute, chair, Cancer Committee, TriStar Centennial Medical Center, discusses findings from the phase 1 BL-B01D1-101 trial (NCT05194982) investigating the efficacy and safety of the EGFR- and HER3-directed antibody-drug conjugate (ADC) BL-B01D1 in patients with locally advanced or metastatic solid tumors, including non–small cell lung cancer (NSCLC).
